European urology最新文献

{"title":"Re: Can Aydogdu, Laura Bukavina, Liang Cheng, et al. Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.05.030.","authors":"Renate Pichler, José Daniel Subiela","doi":"10.1016/j.eururo.2026.07.037","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.037","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148852073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Surgical Data Capture to Surgical AI: Democratising Surgery Requires Open Data Governance Referring to the article: \"When the Platform Owns the Procedure: Intellectual Property Rights and Robotic Surgery\".","authors":"Karl-Friedrich Kowalewski, Pieter De Backer, Thomas Knoll, Christian Wagner","doi":"10.1016/j.eururo.2026.08.006","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.08.006","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148835734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.023.","authors":"Sho Todo, Keiichiro Kitahama, Kentaro Inamura","doi":"10.1016/j.eururo.2026.07.032","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.032","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148803587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.","authors":"Umberto Capitanio, Axel Bex, Grant D Stewart, Alessandro Larcher, Francesco Montorsi","doi":"10.1016/j.eururo.2026.07.034","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.034","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.","authors":"Leonardo Quarta, Paolo Zaurito, Alessandro Viti, Andrea Cosenza, Simone Scuderi, Francesco Barletta, Vito Cucchiara, Armando Stabile, Lucia Dambrosio, Elio Mazzone, Nazario Tenace, Giorgio Brembilla, Francesco De Cobelli, Ana Maria Samanes Gajate, Cristiano Pini, Maria Picchio, Arturo Chiti, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia","doi":"10.1016/j.eururo.2026.07.027","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.027","url":null,"abstract":"<p><p>We report the results of a prospective trial aimed at describing the feasibility and accuracy of prostate-specific membrane antigen (PSMA) radio-guided surgery (RGS) during robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND) in patients with prostate cancer (PCa). This was a phase 2 study (NCT04832958) that enrolled 82 patients with localized PCa and a lymph node invasion (LNI) risk >5%. All patients underwent preoperative PSMA positron emission tomography (PET). [^99mTc]Tc-PSMA-I&S was administered intravenously the day before surgery, followed by single-photon emission computed tomography/computed tomography. Side effects, perioperative outcomes, and the performance characteristics of PSMA-RGS for LNI detection were measured. A total of 62 patients completed all study procedures and were included in the final analyses. Median blood loss and length of stay were 50 ml and 4 d, respectively. No adverse events after tracer administration or intraoperative complications were recorded. Four patients experienced a Clavien-Dindo grade 3 complication within 30 d. Overall, PSMA-RGS identified two additional patients with high-risk PCa and pathologically node-positive (pN1) disease compared with preoperative PSMA PET, exhibiting a lower positive predictive value (PPV) and a similar negative predictive value (NPV) in the per-patient analysis (PPV: 50% vs 70%; NPV: 83% vs 83%). The PPV and NPV at per-region analysis in patients with molecular imaging node-positive (miN1) disease were higher for PSMA-RGS than for PSMA PET (PPV: 55% vs 42%; NPV: 85% vs 81%). In conclusion, PSMA-RGS identifies additional patients with pN1 disease missed by preoperative PSMA-PET among men with high-risk PCa, and extends the ePLND template in patients with miN1 disease, in whom PSMA PET underestimates the nodal burden. However, its NPV is suboptimal for avoiding ePLND in patients with PCa who have a LNI risk >5% and negative PSMA-RGS findings during RARP.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FASTRACK II: Expanding the Role of SABR in Localized Renal Cell Carcinoma.","authors":"Julian Philipp Layer, Eleni Gkika, Niklas Klümper","doi":"10.1016/j.eururo.2026.07.030","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.030","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.","authors":"Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo, Ray McDermott, Erik Briers, Beatrice Fournier, Olga Basova, Bert Dhont, Marcell Csanádi, Silke Gillessen, Bertrand Tombal","doi":"10.1016/j.eururo.2026.07.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.020","url":null,"abstract":"<p><p>For patients with metastatic hormone-sensitive prostate cancer who achieve deep prostate-specific antigen responses with androgen deprivation therapy plus an androgen receptor pathway inhibitor, continuous treatment until progression may not be necessary. EORTC 2238 tests whether an intermittent strategy can safely reduce toxicity, improve quality of life, and lessen health care resource use.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-port Robotic Platforms in Functional Urology: A Paradigm Shift in Pelvic Reconstructive and Continence Surgery.","authors":"Georges Abi Tayeh, Simone Crivellaro, Véronique Phé","doi":"10.1016/j.eururo.2026.07.024","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.024","url":null,"abstract":"","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.","authors":"Amar U Kishan, Yilun Sun, Christopher C Parker, Paul Sargos, Matthew Sydes, Sylvie Chabaud, Meryem Brihoum, Stephane Supiot, Igor Latorzeff, Stephane Guerif, Tahmineh Romero Kalbasi, Michael L Steinberg, Luca F Valle, Kekoa Taparra, Matthew J Farrell, Jonathan E Shoag, Jorge A Garcia, Jason R Brown, Matthew B Rettig, Adam E Singer, Nikita Baclig, Robert E Reiter, Scott Eggener, Wayne Brisbane, Soumyajit Roy, Angela Y Jia, Ting Martin Ma, Nicholas G Nickols, Jason A Efstathiou, James J Dignam, Wendy F Seiferheld, Alan Pollack, Howard M Sandler, Paul L Nguyen, Pascal Pommier, Daniel E Spratt","doi":"10.1016/j.eururo.2026.07.013","DOIUrl":"10.1016/j.eururo.2026.07.013","url":null,"abstract":"<p><strong>Background and objective: </strong>A recent individual patient data (IPD) meta-analysis of randomized trials found a limited overall survival (OS) and metastasis-free survival (MFS) benefit to the addition of hormonal therapy (HT) to postoperative radiotherapy for prostate cancer in patients with pre-radiotherapy prostate-specific antigen (PSA) ≤0.5 ng/ml. We evaluated whether the OS and MFS benefits of adding HT might be significantly modified by an increasing count of adverse pathological features (adverse feature count [AFC]).</p><p><strong>Methods: </strong>We obtained IPD from five randomized phase 3 trials of postoperative radiotherapy ± HT. AFC was prospectively defined as the sum (0-4) of grade group 4-5 disease, seminal vesicle invasion, positive surgical margins, and extracapsular extension. Intention-to-treat one-stage meta-analytical models were used. We also evaluated the interaction of the benefit of HT with a restricted score comprising only GG4-5 and seminal vesicle invasion (range 0-2), as a pre-specified sensitivity analysis.</p><p><strong>Key findings and limitations: </strong>We included IPD from 4781 patients with a median follow-up of 9.1 yr. AFC was independently prognostic for OS and MFS. However, AFC did not significantly modify the OS benefit of HT (interaction hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.79-1.10; p = 0.4) or MFS benefit (interaction HR, 0.88; 95% CI, 0.77-1.01; p = 0.08). Results were similar when AFC was analyzed categorically and in high-risk subsets, and when the restricted AFC score was used.</p><p><strong>Conclusions and clinical implications: </strong>Overall, the data suggest that although adverse pathological features are prognostic, they do not appear predictive of HT benefit after postoperative radiotherapy, which is relevant for patients with a PSA ≤0.5 ng/ml before radiation.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.","authors":"Matthew D Galsky, Andrea Necchi","doi":"10.1016/j.eururo.2026.07.014","DOIUrl":"https://doi.org/10.1016/j.eururo.2026.07.014","url":null,"abstract":"<p><p>Clinical complete response to systemic therapy for patients with muscle-invasive bladder cancer should be approached as rigorously as one would approach any biomarker. This requires uniform assessments and consistent definitions. Emerging data indicate that clinical response assessment may allow individualized treatment for patients with muscle-invasive bladder cancer but further studies are needed.</p>","PeriodicalId":94000,"journal":{"name":"European urology","volume":" ","pages":""},"PeriodicalIF":25.2,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}